Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 Diabetes

Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 Diabetes Using Metformin or Metformin Plus a Thiazolidinedione

The purpose of this study is to test the hypothesis that in patients with type 2 diabetes, the addition of exenatide will result in lower time-averaged serum glucose during a 24-hour period, compared with placebo.

Inclusion Criteria:

• Subject has an HbA1c between 7.0% and 10.0%, inclusive.
• Subject has a body mass index (BMI) >25 kg/m^2 and <50 kg/m^2.
• Subject is on a stable dose of metformin or metformin plus a thiazolidinedione.

Exclusion Criteria:

• Subject has been treated with any of the following medications: *exogenous insulin for more than 1 week within 3 months of screening, *sulfonylureas or meglitinides within 2 months of screening, *alpha-glucosidase inhibitors within 2 months of screening, *pramlintide acetate injection within 2 months of screening.
• Subject has received exenatide, GLP-1 analogs, DPP-IV inhibitors, or has participated in this study previously.